Defined Bioscience

Defined Bioscience specializes in serum-free stem cell media. Through my Seminar in World Business class, our graduate consulting team was asked to help the company assess entering the Japanese market: how labs and institutions buy, what it takes to get product across the border, and who could distribute it.

I owned three pieces of the research: the market opportunity, customer switching costs, and Japanese trade policy. I worked from market reports, Japanese government sources and the U.S. Commercial Service, alongside the team's interviews with the client and a senior research scientist.

• Demand is real and rising. Japan approved the world's first two iPS cell therapies in March 2026, and MarketsandMarkets projects the country's cell culture market to grow about 12.8% a year through 2031, with media and reagents the largest segment.
• Switching costs split the market. Research labs can test a new medium cheaply if they are shown performance data. Clinical and GMP programs rarely change a raw material once a process is locked in.
• Trade policy is not the barrier. Culture media from the U.S. enters Japan duty-free, and the 10% import consumption tax is paid by the importer of record. The real hurdles are Japanese-language labeling and documentation, local standards, and relationships.

• Win research labs first with free samples, application notes and Japanese-language performance data.
• Reach clinical programs and contract manufacturers before they lock in a medium, since new and expanding programs are the best entry point.
• Use a PMDA Master File to reduce the paperwork for GMP customers.

This is the work I want to do more of: figuring out where a company should grow next, and what stands between it and its first customers there.